Other phase Ib/II clinical trials are evaluating the efficacy of olaparib in combination with capivasertive (AKT inhibitor) or vistusertib (mTORC1/2 inhibitor) in BRCA1/2-mutated recurrent endometrial and ovarian cancer (NCT02208375). Here, AKT1 is linked to ovarian cancer.